Member Info for Lionel1

I have a strong feeling it is something to do with the LinkedIn comment .

My AI tool thinks …

Based on the search results, CYP2C19 point-of-care testing in community pharmacies appears to be a feasible and promising approach for guiding antiplatelet therapy:

1. A proof-of-concept study evaluated CYP2C19-guided de-escalation of prasugrel/ticagrelor to clopidogrel using point-of-care testing in community pharmacies[1][2]. Key findings include:

- 144 patients were tested across 27 pharmacies, with a 98.6% success rate in obtaining results.

- 92% of patients found the pharmacy a suitable location for testing.

- 86% of pharmacists thought the testing added value.

- The estimated net cost was €43 per patient, with potential for cost savings if de-escalation rates increased.

2. Point-of-care CYP2C19 testing in pharmacies can help guide antiplatelet therapy selection, potentially improving cardiovascular outcomes and reducing costs for patients on P2Y12 inhibitors like prasugrel or ticagrelor[1][2].

3. While laboratory-based testing is preferred for detecting a wider range of alleles, point-of-care tests like the Genedrive CYP2C19 ID Kit are recommended when laboratory testing is unavailable or delayed[3].

4. A time and motion study found that pharmacist-provided point-of-care CYP2C19 testing and consultation in a simulated community pharmacy setting took an average of 53 minutes per patient[4].

Overall, CYP2C19 point-of-care testing in pharmacies appears feasible and may help optimize antiplatelet therapy, though implementation challenges and the need for pharmacist training should be considered.

@Gloria , This is what I have mentioned other day , GDR Poc will be used by all pharmacies near future .

Good Article .

The guidance suggests that utilising pharmacies for point-of-care testing can enhance the accessibility and convenience of the testing process, particularly in community settings.

To address this, the committee agreed that blood samples or cheek swabs for genotype testing could be collected at local pharmacies, GP surgeries, or even in patients’ homes, provided certain conditions are met.

https://www.pharmacy.biz/news/pharmacists-pivotal-in-genotype-testing-for-stroke-and-tia-patients-says-nice-guidance/

Papaya good at sprouting nonsense ..

https://youtu.be/ke3vSgB0tyU?si=qwnVvDJTJBbcEb_l

Listen to Gino

I think it will be on November 19th 2024 , seen somewhere .

This is what my AI tool Perplexity said about the uptake ..

Based on the search results, here are the key points regarding NICE's implementation plan for CYP2C19 point-of-care testing across the NHS in the UK:

1. NICE has recommended the use of CYP2C19 genotype testing to guide clopidogrel use after ischemic stroke or transient ischemic attack.

2. NICE is developing implementation tools to help NHS organizations put this guidance into practice, including:

- A resource impact tool

- A case study

- Worked examples and pathways.

3. The implementation process will likely involve:

- Setting up quality assurance processes for point-of-care tests.

- Determining who will be responsible for conducting quality assurance.

- Evaluating performance in clinical settings, as done at Manchester Royal Infirmary.

- Pilot testing at larger stroke units to establish benefits across wider populations.

4. Cost-effectiveness analysis shows CYP2C19 testing could lead to significant NHS savings:

- £512 less expensive per patient compared to no testing

- Potential annual savings of over £160 million for the NHS[3]

5. Implementation challenges include:

- Variability in testing offered across the NHS

- Determining the best ways to introduce testing for patients who have just experienced a stroke or TIA.

6. The rollout will likely be gradual, with initial adoption at some hospitals following the NICE recommendation, rather than immediate universal uptake.

While NICE has recommended the use of CYP2C19 testing, the full implementation plan is still being developed, with tools and resources expected to be released to support NHS-wide adoption.

Well said jazzim.

@system , lol you are already sick .

@Gloria , MT RNR1.

Lol Tkevin , I use a new AI app called “Perplexity” which is better than ChatGpt , try it out ..

Based on the NICE recommendation, Genedrive is expected to make several specific changes to its sales strategy for 2024:

1. Active UK commercialization: Following the final NICE recommendation due on July 10, 2024, Genedrive intends to actively pursue commercialization of the CYP2C19-ID Kit in the UK.

2. NHS market focus: With NICE recommending Genedrive as the preferred point-of-care platform for CYP2C19 genotyping in the NHS, the company will likely prioritize sales efforts targeting UK hospitals and healthcare providers.

3. Expanded product portfolio promotion: Genedrive will likely emphasize its growing pharmacogenetic testing portfolio, including both the CYP2C19-ID and MT-RNR1 tests, which have received NICE recommendations.

4. European market preparation: The company is pursuing CE-IVD certification for commercialization in the European Union and other countries recognizing CE-IVD, expected in early 2025. This suggests a strategy to expand sales beyond the UK market.

5. Clinical partnerships: Genedrive will continue its partnership with clinical genetics collaborators in Manchester under the DEVOTE programme to supplement existing clinical performance data, supporting both UK and EU certifications.

6. Emphasis on cost-effectiveness: The sales strategy will likely highlight the cost-effectiveness of Genedrive's platform, as emphasized in the NICE recommendation.

These changes indicate a shift towards more aggressive commercialization in the UK, preparation for European expansion, and a focus on promoting the unique features and cost-effectiveness of Genedrive's pharmacogenetic testing platform.

I think Party Just started , SP will retrace but you will see pull backs on the way up ..

Genedrive's CYP2C19 point-of-care (POC) genotyping technology is gaining traction in the Middle East, particularly in countries like Saudi Arabia, Qatar, Bahrain, and Dubai. This technology is crucial for personalized medicine, especially in cardiology, where CYP2C19 polymorphisms significantly impact the effectiveness of clopidogrel, a common antiplatelet drug. Studies have shown varying allele frequencies of CYP2C19*2 and CYP2C19*3 in different populations, influencing drug response and necessitating genotype-guided therapy to improve patient outcomes, The adoption of such technologies in these regions underscores a commitment to advancing healthcare through precision medicine.

Thank you Espen , I am in US at the moment , back and forth all this month concluding some business . I know where this is going, A very good company in making .. it will be eventually taken over for premium. Sit back and relax , no need to argue with some stupids.. GL to all

Thank you Woody .

CYP2C19 testing is expected to significantly impact patient outcomes in the NHS, particularly for stroke patients:

1. It will enable personalized antiplatelet therapy selection, allowing clinicians to prescribe more effective medications for patients with CYP2C19 loss-of-function variants who may not respond well to clopidogrel.

2. The rapid point-of-care testing (results in about an hour) will allow for timely treatment decisions, crucial in acute stroke care.

3. It may reduce the risk of secondary strokes and hospital readmissions. A cost-effectiveness analysis showed that using a rapid genetic test could lead to £512 savings per patient compared to no testing.

4. The test could potentially improve patients' quality of life by ensuring they receive the most appropriate antiplatelet therapy.

5. On a larger scale, the implementation of CYP2C19 testing could result in significant cost savings for the NHS, with estimates suggesting a potential value of over £160 million annually.

6. It may help reduce ischemic events in CYP2C19 loss-of-function carriers by guiding the use of alternative P2Y12 inhibitors like ticagrelor or prasugrel, which have shown a significant reduction in ischemic events for these patients.

By enabling more precise and timely treatment decisions, CYP2C19 testing has the potential to improve overall patient care, reduce complications, and optimize resource utilization within the NHS.

Based on the available search results, CYP2C19 point-of-care tests appear to be cost-effective for use in the NHS, particularly for guiding antiplatelet therapy selection in stroke patients. Key findings include:

7.CYP2C19 testing strategies resulted in positive incremental QALYs (quality-adjusted life years) and lower costs compared to no testing in both ischemic stroke and transient ischemic attack populations.

8. A cost-effectiveness analysis found that CYP2C19 testing was £512 less expensive per patient compared to no testing and generated 0.107 additional QALYs. This makes CYP2C19 testing the dominant strategy, being both cheaper and more effective.

9. The testing strategy generated a net health benefit of 0.133 QALYs per patient tested or a net monetary benefit of £2,652 per patient.

10. Across an assumed patient population of 60,424, this equates to a total net health benefit of 8,012 QALYs or a total net monetary benefit of £160,244,448.

11. Sensitivity analyses confirmed that CYP2C19 testing is highly likely to be cost-effective and likely to be cost-saving even when accounting for uncertainty in the available evidence.

These findings suggest that implementing CYP2C19 point-of-care tests in the NHS could lead to significant health improvements and cost savings, particularly in the management of stroke patients.

Not reading this board lately ..

Implementing the Genedrive CYP2C19-ID test in the NHS is expected to be cost-effective compared to not testing. The test costs £100 (excluding VAT) per use and helps identify patients who may not metabolize clopidogrel effectively, allowing for alternative treatments to reduce the risk of recurrent strokes. NICE's systematic review concluded that CYP2C19 genetic testing is beneficial and cost-effective, as it can prevent suboptimal responses to clopidogrel, which affects 20-30% of the UK population and up to 50-60% in certain ethnic groups.

Is not worrying that somebody not invested in this share and spending 24/7 here , you are mentally ill W**cker.

Excellent , Thank you Johnny ..

@Gloria , This is what I was talking about other day, I still couldn’t find the original podcast where they were discussing about collecting the genomic data for all patients .. same thing they were already doing in Belgium and Italy , they are using the lab and POC both , they are using Genomix cube for POC at the moment , GDR is much advanced than the cube.

https://youtu.be/9h9_XPf1Pyg?feature=shared

I didn’t see the NHS comments document before , Thank you

@Starres , You remind me Dave from movie Penguins of Madagascar:-) , Give it up mate , you fighting the loosing battle ..